Prevalence of primary Helicobacter pylori antibiotic resistance in Europe over the past four decades
Abstract
BACKGROUND & AIMS: Antibiotic resistance is a major determinant of the efficacy of Helicobacter pylori (H. pylori) eradication treatment. Our objective was to evaluate the prevalence and geographical distribution of primary antibiotic resistance in patients infected with H. pylori across Europe over the last four decades.
METHODS: Bibliographical searches were conducted from 1990 to 2024 in the PubMed database with no language restrictions. Selected studies evaluated the primary resistance of H. pylori to clarithromycin, metronidazole, levofloxacin, amoxicillin, tetracycline and rifampicin in adults. Data were grouped by country and time intervals (1990-1999, 2000-2009, 2010-2019, 2020-2024) to identify potential trends. High resistance thresholds were defined as ≥15% for clarithromycin and levofloxacin, and ≥30% for metronidazole.
RESULTS: A total of 216 studies were included: 188 with information on clarithromycin resistant strains (86,917 patients), 138 on metronidazole (83,995 patients), and 77 on levofloxacin (40,619 patients). The overall prevalence of primary resistance to clarithromycin, levofloxacin, and metronidazole was 16% (95% confidence interval, 7-24%), 18% (10-21%), and 33% (29-36%), respectively. Primary resistance to clarithromycin and levofloxacin increased steadily across all periods, reaching 24% and 21%, respectively, in the most recent period. Primary resistance to amoxicillin, tetracycline, and rifampicin remained low, at 2.3%, 1%, and 4%,…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.